Psilocybe Natalensis: What Makes It Unique?

A relatively new psilocybin mushroom species, P. natalensis, is beginning to draw some attention away from cubensis. Learn more in our guide.

For over half a century, Psilocybe cubensis has been the most widely studied and documented psilocybin mushroom species – recognized across the mycology community for its distinctive morphology, geographic range, and well-characterized spore profile.

Now, a relatively new psilocybin mushroom species, Psilocybe natalensis (P. natalensis), is beginning to draw serious attention away from Cubensis among mycologists, researchers, and mushroom enthusiasts. Discovered in South Africa in 1995, it has gained traction in the U.S. over the past several years – partly for its distinct physical characteristics, and partly because of a fascinating case of mistaken identity that goes to the heart of what makes this species so interesting.

But there’s a layer of complexity worth understanding before diving in: much of what has been circulating in the U.S. under the Natalensis name may not actually be P. natalensis at all — and that distinction turns out to be one of the more compelling stories in recent psilocybin mycology.

In this guide, we’ll cover its origins, defining physical traits, how it compares to P. cubensis, its current legal status, the newly identified cousin species creating the confusion, and what the research community is saying about its therapeutic potential.

History of Psilocybe Natalensis

P. Natalensis was the first psilocybin mushroom species to be formally identified in South Africa.

It was found growing naturally on bovine dung in 1995 in KwaZulu-Natal, a coastal province known for its diverse landscapes, from subtropical beaches to savannah grasslands filled with wildlife and rolling mountains. 

KwaZulu-Natal also holds deep historical significance. It was here that Nelson Mandela – South Africa’s iconic anti-apartheid leader and Nobel Peace Prize laureate – was arrested on August 5, 1962. This pivotal event marked the beginning of his 27-year imprisonment, a sacrifice that helped dismantle the apartheid regime and led to his becoming the nation’s first democratically elected Black president in 1994. 

The magic mushroom takes its name from KwaZulu-Natal, hence the term Natalensis.

Initially, P. natalensis was mistaken for a novel variety of Psilocybe cubensis. However, upon closer analysis by a team of prominent mycologists, including Jochen Gartz and Derek Reid, it was determined to be a unique species altogether and named Psilocybe natalensis.

How to Spot P. Natalensis

“Nats” – also known as “Natal Super Strength” for its reputed high potency, which some believe exceeds that of most P. cubensis strains – closely resembles Psilocybe cubensis in appearance, but also expresses its own distinct phenotypes that set it apart on closer examination.

Before getting into those characteristics, there’s an important context worth establishing: much of what has been circulating in the U.S. as Natalensis may actually be Psilocybe ochraceocentrata aff. natalensis – a newly identified species that was unknowingly masquerading as Natal Super Strength. Understanding the difference between the two is part of what makes accurate identification of this genus genuinely interesting right now.

With that context in place, here are the key physical characteristics of true P. natalensis:

Cap

The cap of Psilocybe natalensis starts off cone-shaped and gradually flattens as it develops, often retaining a small, nipple-like central bump called an umbo.

Fully mature caps typically range from 1.4 to 6 cm (0.55 to 2.36 inches) in diameter, placing them within the small to medium size class of psilocybin mushrooms. The surface is often sticky to the touch and may appear slightly glossy when fresh.

Fresh specimens may also show a faint translucency near the cap’s margin, lending them a slightly luminous appearance that sets them apart from other Psilocybe species.

In early stages, the cap displays a rich brown to golden-brown coloration, which progressively lightens – especially near the edges – as they grow transitioning into soft caramel or pale yellow tones. 

A key identifying trait is the cap’s tendency to bruise blue when handled or injured, a reaction caused by the oxidation of psilocybin, the naturally occurring psychedelic compound responsible for Natalensis’s mind-altering effects.

Stem

P. natalensis features thick and sturdy stems, ranging in color from white to pale cream. 

Compared to many other psilocybin species, these stems are noticeably more robust and exhibit blue bruising when handled, just like their caps.

Each stem grows to about 5.8–10 cm (2.3–3.9 inches) in length and maintains a uniform diameter from base to cap, giving it a straight, column-like profile.

Spores

When viewed under a microscope, Natalensis spores appear dark purple-brown, similar to those of popular Psilocybin cubensis magic mushroom strains such as Stargazer and Tidal Wave.

They’re produced on tightly spaced gills beneath the cap that shift from pale cream to light gray as the mushroom matures. 

The mushroom spores are elliptical and measure 11–14 by 7–9 micrometers – a standard unit in taxonomy that isn’t converted to inches or centimeters due to its microscopic scale.

For microscopy and taxonomic use only, PNW Spore offers the highest-quality P. natalensis spore syringes in 10cc quantities.

Mycelium

Mycelium is the mushroom’s root system, a network that spreads through the soil or growing material to absorb nutrients. 

These nutrients fuel the development of the fruiting body, the part of the mushroom that eventually appears above the surface.

Psilocybe natalensis features a unique type of mycelium known as rhizomorphic mycelium. This form produces thick, rope-like strands that resemble plant roots and spreads rapidly through the substrate, promoting faster and more vigorous growth.

But it’s not just about speed. Rhizomorphic mycelium also dominates the microbial environment, naturally suppressing mold, bacteria, and other contaminants.

The Newly Discovered Cousin: P. ochraceocentrata

As interest in P. natalensis has grown in the U.S., so has a genuinely interesting taxonomic question: is what’s been circulating here actually P. natalensis at all?

Research and sequencing work has identified a closely related but distinct species – Psilocybe ochraceocentrata aff. natalensis – that has been unknowingly circulating in the United States as Natal Super Strength. The “aff.” designation signals that this is a species affined to P. natalensis but not yet fully defined – new enough that the scientific community is still working out its precise classification. You can view the current iNaturalist taxonomy entry for P. natalensis for reference.

What makes this particularly interesting is where ochraceocentrata sits on the phylogenetic tree: it appears to be more closely related to P. cubensis than to true P. natalensis, based on both physical and microscopy characteristics. The genetics PNW Spore carries is Psilocybe ochraceocentrata aff. natalensis – and understanding the differentiating physical characteristics is part of what makes this species worth studying.

The key distinctions identified during sequencing of true P. natalensis include loss of pigmentation at maturity and fewer, more elongated spores. P. ochraceocentrata, by contrast, produces medium-sized caps with dark, dense spore prints, and individual spores that are more ellipsoid to sub-ellipsoid in shape – characteristics that place it closer to cubensis on the spectrum.

PNW Spore is actively following the research as this species moves toward clearer taxonomic classification.

Legal Status of P. Natalensis

The legal landscape for P. natalensis is worth understanding clearly. As a psilocybin-containing species, it carries the same federal Schedule I classification as other magic mushrooms – meaning cultivation and possession of the mushroom itself is governed by the same laws that apply across this genus. This classification reflects the federal position that psilocybin has high potential for abuse and no currently accepted medical use – a designation that has increasingly come into tension with a growing body of clinical research, including its studied impact on depression.

That research momentum has also been a driver of policy change at the state level. Laws surrounding psychedelics are evolving, and the landscape varies significantly by jurisdiction. For a full breakdown, here’s our state-by-state guide.

The legal picture for P. natalensis spores is different. Spores themselves do not contain detectable psilocybin or psilocin, which is why they’re legal to purchase for microscopy and educational purposes in most U.S. states. There are exceptions: California, Georgia, Florida, and Idaho have prohibited psilocybin mushroom spores regardless of intended use. Before purchasing or handling P. natalensis spores in any form, confirm the regulations specific to your state.

Potential Therapeutic Applications

From a research perspective, P. natalensis is drawing attention on two fronts. First, emerging studies suggest compounds in this species may have antioxidant and anti-inflammatory properties that appear to suppress the production of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) in macrophages – white blood cells central to immune regulation. When cytokine production goes unchecked, the resulting immune overreaction is linked to a range of autoimmune and inflammatory conditions. By modulating cytokine levels, compounds in P. natalensis may help restore immune balance, though further research is needed.

Beyond its anti-inflammatory potential, P. natalensis is gaining recognition for its psilocybin content and what that means for mental health research. There is a growing body of scientific evidence showing that psilocybin can be more effective in managing depression, anxiety, PTSD, substance use disorders, and even cluster headaches and migraines. A Yale School of Medicine study established that one dose of psilocybin significantly reduced migraine frequency over a two-week period – and Yale currently has a follow-up mechanistic study on psilocybin in headache disorders actively recruiting, with results expected by the end of 2026.

These findings are reshaping the medical conversation around psychedelics, positioning them as credible candidates for conditions that have long resisted conventional treatment.

Want to learn more about the potential therapeutic applications of psilocybin mushrooms? Don’t miss our article on the 5 Potential Health Benefits of Magic Mushrooms.

Sources

1. https://www.mdpi.com/2223-7747/9/9/1127 
2. https://pubmed.ncbi.nlm.nih.gov/33184743/